Related Experiment Video
Updated: May 31, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Optimizing Anticoagulation Therapy when Utilizing Mechanical Circulatory Support Devices
Maurizio Bertaina1, Luca Franchin1, Aleksandra Gąsecka2
1Division of Cardiology, San Giovanni Bosco Hospital, ASL Città di Torino, Turin, Italy.
Abstract:
Hemorrhagic complications are frequent and clinically significant in patients undergoing mechanical circulatory support (MCS), occurring in 10% to 40% of cardiogenic shock cases and 5% to 10% of high-risk percutaneous coronary interventions. These events prolong hospitalization, increase morbidity, and adversely impact outcomes. This review examines the prevention and management of bleeding during MCS implantation, prolonged support, and removal. Access-site complications-predominantly from large-bore sheaths-can be mitigated through pre-procedural vascular imaging, ultrasound-guided puncture, and proficiency with large-bore closure techniques. During prolonged support, systemic bleeding may result from device-related hemocompatibility issues, combined antithrombotic therapy, and acquired coagulopathies.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Heart Failure VI: Adjunct Therapies
Peripheral Artery Disease III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis IV: Nursing Management

